Susceptibility to Ceftriaxone-sulbactam-EDTA in gram negative MDR & non-MDR isolates at tertiary care centre JNMCH Aligarh, Uttar Pradesh

Authors

  • Syed Hilal Husain Department of Microbiology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India
  • Fatima Khan Department of Microbiology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India
  • Asfia Sultan Department of Microbiology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India
  • Anees Akhtar Department of Microbiology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India

DOI:

https://doi.org/10.31344/ijhhs.v7i700.552

Keywords:

Ceftriaxone-sulbactam-EDTA, susceptibility, multi-drug resistant

Abstract

Introduction: A rapid increase in multidrug-resistant (MDR) is being reported across India. Ceftriaxone-sulbactam-EDTA (CSE) is a promising therapeutic option available in cases of infections caused by ESBL and MBL producing pathogens proving to be a carbapenem-sparing antibiotic. However, CSE effectiveness needs to be evaluated due to rapidly increasing antimicrobial resistance.

Objectives: Following prospective observational study was directed to generate data on in-vitro susceptibility of MDR and NON-MDR to Ceftriaxone-sulbactam-EDTA (CSE).

Materials and Methods: Gram negative bacterial isolates cultured from various nonrepetitive clinical samples of indoor and outdoor patients of a tertiary care centre of UP for a period of 9 months (1 April 2022 to 31 December 2022) were included in the study. Antimicrobial susceptibility testing to antibiotics was done using Kirby-Bauer disk diffusion and VITEK methods.

Results: During study period, 82.3% (229/278) and 17.6% (49/278) of MDR and Non- MDR gram negative isolates respectively. Among the isolates 51% of MDR and 95% of Non- MDR were found to be susceptible to CSE.

Conclusions: Present study shows that in-vitro susceptibility to CSE varies from 51% to 95% depending on the organism. A trend of increasing resistance in multidrug-resistant (MDR) organisms is being reported across all isolates. Ceftriaxone-sulbactam-EDTA fixed dose combination is a promising therapeutic option in cases of infections caused by MDR (especially ESBL and MBL producing pathogens) acting as carbapenem-sparing antibiotics.

International Journal of Human and Health Sciences Supplementary Issue 02: 2023 Page: S149-S158

Downloads

Published

2023-05-30

How to Cite

Husain, S. H., Khan, F., Sultan, A., & Akhtar, A. (2023). Susceptibility to Ceftriaxone-sulbactam-EDTA in gram negative MDR & non-MDR isolates at tertiary care centre JNMCH Aligarh, Uttar Pradesh. International Journal of Human and Health Sciences (IJHHS), 7(700), S149-S158. https://doi.org/10.31344/ijhhs.v7i700.552

Issue

2023: Supplementary Issue-2: 2023

Section

Original Articles

License

Copyright (c) 2023 Syed Hilal Husain, Fatima Khan, Asfia Sultan, Anees Akhtar

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in the International Journal of Human and Health Sciences agree to the following terms that:

  1. Authors retain copyright and grant International Journal of Human and Health Sciences the right of first publication of the work.

  2. Creative Commons Licence
    Articles in International Journal of Human and Health Sciences are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.

Most read articles by the same author(s)